Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

MedImmune FluMist complete response

This article was originally published in Pharmaceutical Approvals Monthly

  • News

Executive Summary

MedImmune submits FluMist "complete response" Aug. 26 to FDA's second action letter for the nasal flu vaccine, dated July 10 (Pharmaceutical Approvals Monthly, August 2002, In Brief). Wyeth has begun producing 4 mil. doses of FluMist in hopes of launching for the 2002 flu season; the doses will not be valid for the 2003 flu season. MedImmune says a 2002 launch would be "tight," as approval would be needed by Sept.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

NGGT Progresses First US Gene Therapy Trials For Rare Conditions

'We Are Not Waiting To Be Replaced': Medical Affairs Pros Take On GPT-4o

Japan Reimburses Zolbetuximab, To Cut Price Of Imfinzi, Others

Korea’s Clinical Trial Approvals Up 10%, But Still Below Pandemic Peak

See All
UsernamePublicRestriction

Register

PS002027

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By